期刊文献+

MiR-451 inhibits proliferation of esophageal carcinoma cellline EC9706 by targeting CDKN2D and MAP3K1 被引量:6

下载PDF
导出
摘要 AIM To investigate the underlying molecularmechanisms of miR-451 to inhibit proliferation ofesophageal carcinoma cell line EC9706.METHODS: Assays for cell growth, apoptosis andinvasion were used to evaluate the effects of miR-451expression on EC cells. Luciferase reporter and Westernblot assays were used to test whether cyclin-dependentkinase inhibitor 2D (CDKN2D) and MAP3K1 act as majortargets of miR-451.RESULTS: The results showed that CDKN2D andMAP3K1 are direct targets of miR-451. CDKN2D andMAP3K1 overexpression reversed the effect of miR-451.MiR-451 inhibited the proliferation of EC9706 bytargeting CDKN2D and MAP3K1.CONCLUSION: These findings suggest that miR-451might be a novel prognostic biomarker and a potentialtarget for the treatment of esophageal squamous cellcarcinoma in the future.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第19期5867-5876,共10页 世界胃肠病学杂志(英文版)
基金 Supported by National Natural Science Foundation of China,No.81301726
  • 相关文献

参考文献30

  • 1Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophagealcancer: Orient to Occident. Effects of chronology, geography andethnicity. J Gastroenterol Hepatol 2009; 24: 729-735 [PMID:19646015 DOI: 10.1111/j.1440-1746.2009.05824.x].
  • 2Dawsey SP, Tonui S, Parker RK, Fitzwater JW, Dawsey SM,White RE, Abnet CC. Esophageal cancer in young people: a caseseries of 109 cases and review of the literature. PLoS One 2010; 5:e14080 [PMID: 21124934 DOI: 10.1371/journal.pone.0014080].
  • 3Baxi SH, Burmeister B, Harvey JA, Smithers M, Thomas J.Salvage definitive chemo-radiotherapy for locally recurrentoesophageal carcinoma after primary surgery: retrospective review.J Med Imaging Radiat Oncol 2008; 52: 583-587 [PMID: 19178634DOI: 10.1111/j.1440-1673.2008.02023.x].
  • 4Matsushima K, Isomoto H, Kohno S, Nakao K. MicroRNAs andesophageal squamous cell carcinoma. Digestion 2010; 82: 138-144[PMID: 20588024 DOI: 10.1159/000310918].
  • 5Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI:10.1038/nrc1997].
  • 6Esteller M. Cancer Epigenetics for the 21st Century: What's Next-Genes Cancer 2011; 2: 604-606 [PMID: 21941616 DOI: 10.1177/1947601911423096].
  • 7Chen WX, Ren LH, Shi RH. Implication of miRNAs forinflammatory bowel disease treatment: Systematic review. World JGastrointest Pathophysiol 2014; 5: 63-70 [PMID: 24891977 DOI:10.4291/wjgp.v5.i2.63].
  • 8Kozomara A, Griffiths-Jones S. miRBase: integrating microRNAannotation and deep-sequencing data. Nucleic Acids Res 2011; 39:D152-D157 [PMID: 21037258 DOI: 10.1093/nar/gkq1027].
  • 9Masaki S, Ohtsuka R, Abe Y, Muta K, Umemura T. Expressionpatterns of microRNAs 155 and 451 during normal humanerythropoiesis. Biochem Biophys Res Commun 2007; 364: 509-514[PMID: 17964546 DOI: 10.1016/j.bbrc.2007.10.077].
  • 10Pase L, Layton JE, Kloosterman WP, Carradice D, WaterhousePM, Lieschke GJ. miR-451 regulates zebrafish erythroidmaturation in vivo via its target gata2. Blood 2009; 113: 1794-1804[PMID: 18849488 DOI: 10.1182/blood-2008-05-155812].

同被引文献23

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部